ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
November 30, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
November 21, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving...
ProKidney Reports Third Quarter Financial Results
November 14, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
November 13, 2023 17:02 ET
|
ProKidney
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on...
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
October 30, 2023 16:12 ET
|
ProKidney
WINSTON-SALEM, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
September 05, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
August 10, 2023 16:10 ET
|
ProKidney
WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
July 18, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., July 18, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
July 17, 2023 06:05 ET
|
ProKidney
- Brings more than 20 years of academic and industry experience with extensive expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
June 13, 2023 12:05 ET
|
ProKidney
WINSTON-SALEM, N.C., June 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...